| Literature DB >> 28727771 |
Saskia Persoon1, Mai J M ChinAPaw2, Laurien M Buffart3, Roberto D K Liu4, Pierre Wijermans5, Harry R Koene6, Monique C Minnema7, Pieternella J Lugtenburg8, Erik W A Marijt9, Johannes Brug3, Frans Nollet1, Marie José Kersten4.
Abstract
BACKGROUND: This single blind, multicenter randomized controlled trial aimed to evaluate the effectiveness of a supervised high intensity exercise program on physical fitness and fatigue in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation.Entities:
Mesh:
Year: 2017 PMID: 28727771 PMCID: PMC5519072 DOI: 10.1371/journal.pone.0181313
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Consort diagram.
Baseline demographics and clinical characteristics of participants in the exercise intervention and usual care control group.
| Exercise Intervention group (n = 54) | Usual care control group (n = 55) | |
|---|---|---|
| Gender, male, n (%) | 32 (59) | 37 (67) |
| Age, median(range), years | 53.5 (20–67) | 56 (19–67) |
| Married/Living together, n (%) | 45 (83) | 46 (84) |
| Higher education level, n (%) | 15 (28) | 24 (44) |
| Sports history, yes | 33 (61) | 36 (66) |
| Cancer type, n (%) | ||
| MM | 29 (54) | 29 (53) |
| (N)HL | 25 (46) | 26 (47) |
| Time since auto-SCT, median (range), days | 75 (42–275) | 72 (40–233) |
| Remission status after auto-SCT, n (%) | ||
| CR | 37 (69) | 32 (58) |
| VGPR/PR | 16 (30) | 22 (40) |
| SD/PD | 1 (2) | 1 (2) |
| Comorbidity | 2 (0–6) | 2 (0–5) |
| Neuropathy, n (%) | 14 (26) | 18 (33) |
| Musculoskeletal disorders, n (%) | 38 (70) | 28 (51) |
| Cardiovascular disease or risk factors | ||
| Risk factors, n (%) | 11 (20) | 12 (22) |
| Other, n (%) | 12(22) | 15 (27) |
| Respiratory disease, n (%) | 7 (13) | 7 (12) |
| Other, n (%) | 13 (24) | 8 (13) |
Abbreviations: MM: multiple myeloma; (N)HL: (non-)Hodgkin lymphoma; auto-SCT: autologous stem cell transplantation; CR: Complete response; VGPR: Very good partial response; PR: partial response/remission; SD: Stable disease; PD: progressive disease
a participating in sports at least once a week before diagnoses/relapse.
Effects of the intervention on primary and secondary outcome measures in patients treated with auto-SCT.
| Exercise intervention group (n = 50) | Usual care control group (n = 47) | β (95%CI) | |||
|---|---|---|---|---|---|
| T0 | T1 | T0 | T1 | ||
| VO2peak (mL/kg/min) | 21.7(4.8) | 26.0 (6.3) | 21.2 (5.4) | 24.2 (6.6) | 1.2 (-0.5;2.9) |
| Wpeak (Watt/kg) | 2.0(0.5) | 2.4 (0.7) | 2.0 (0.6) | 2.4 (0.8) | 0.1 (-0.1;0.2) |
| Chair stand test (number) | 15.5 (4.6) | 18.7 (6.0) | 14.5 (4.6) | 17.1 (4.3) | 0.7 (-0.5;1.9) |
| Grip strength (kg) | 35.5 (10.7) | 40.9 (12.0) | 36.9 (10.1) | 41.3 (11.7) | 1.3 (-0.5;3.1) |
| Physical fatigue | 13.2 (4.2) | 9.8 (4.4) | 14.4 (4.8) | 11.1 (5.0) | -0.8 (-2.2;0.7) |
| General fatigue | 12.7 (3.8) | 10.0 (4.5) | 13.5 (4.3) | 11.8 (4.8) | -1.4 (-2.9;0.1) |
| Mental fatigue | 10.0 (4.3) | 9.7 (4.5) | 10.3 (4.8) | 9.7 (4.2) | 0.1 (-1.4;1.6) |
| Reduced activity | 12.2 (4.1) | 9.6 (3.9) | 13.6 (4.5) | 10.8 (4.7) | -0.4 (-1.7;0.8) |
| Reduced motivation | 8.8 (3.8) | 8.0 (3.2) | 9.9 (3.8) | 8.4 (3.3) | 0.1 (-1.0;1.2) |
| BMI (kg/m2) | 25.6 (4.6) | 26.3 (4.7) | 25.1 (3.6) | 25.5 (3.8) | 0.2 (-0.3;0.7) |
| Sum skinfolds (mm) | 61.5 (22.8) | 64.5 (25.1) | 60.8 (24.6) | 64.0 (25.5) | -0.4 (-5.0;4.2) |
| Maximal torque m. quadriceps (Nm) | 145.6 (51.4) | 173.9 (55.9) | 143.9 (52.3) | 165.3 (57.2) | 6.6 (-4.4;17.6) |
| Accelerometry (cpm) | 189.0 (79.2) | 241.4 (92.3) | 197.2 (103.5) | 250.6 (135.0) | -9.8 (-50.1;30.5) |
| PASE-score | 96.9 (99.5) | 131.3 (82.4) | 77.0 (59.3) | 113.5 (97.9) | 1.9 (-30.3;34.1) |
| Global quality of life | 62.2 (18.0) | 75.0 (18.7) | 62.2 (20.6) | 73.4 (18.4) | 2.3 (-4.1;8.6) |
| Physical functioning | 74.5 (18.3) | 83.1 (19.1) | 74.6 (16.9) | 84.1 (15.3) | -2.3 (-6.6;2.0) |
| Role functioning | 60.0 (31.6) | 81.0 (23.8) | 62.8 (29.7) | 73.4 (31.8) | 9.7 (-0.1;19.5) |
| Emotional functioning | 83.2 (14.9) | 86.2 (16.3) | 81.4 (19.1) | 86.0 (14.7) | -1.1 (-6.2;3.9) |
| Cognitive functioning | 87.3 (15.6) | 83.7 (18.0) | 80.5 (21.8) | 82.3 (20.4) | -2.7 (-8.7;3.4) |
| Social functioning | 71.7 (27.2) | 86.0 (20.3) | 74.1 (25.0) | 83.7 (20.4) | 2.5 (-5.1;10.0) |
| Disease symptoms | 16.6 (13.1) | 18.7 (12.8) | 19.8 (14.6) | 18.8 (17.1) | 0.8 (-4.6;6.3) |
| Side effects | 21.5 (9.7) | 10.6 (8.1) | 21.9 (11.8) | 12.1 (8.9) | -0.5 (-4.7;3.7) |
| Anxiety | 4.4 (3.5) | 4.1 (4.1) | 4.3 (3.3) | 3.9 (2.5) | 0.02 (-1.0;1.0) |
| Depression | 3.8 (3.8) | 3.2 (3.4) | 4.1 (3.6) | 2.9 (3.0) | 0.4 (-0.6;1.3) |
Data are mean (±SD).
Abbreviation BMI: Body Mass Index; PASE: Physical Activity Scale for the Elderly.
±Physical fitness assessments: exercise intervention group (n = 48), usual care control group (n = 45).
#Adjusted for age, gender, education level and including random intercept.
+Patients assessed at the AMC only.
‡Patients with multiple myeloma only.
Missing data due to
atechnical problems (n = 8), leakage of/took off face mask/inadequate performance (n = 8), cardiovascular problems (n = 4), change in beta-blockers prescription (n = 2), thrombocytopenia (n = 1);
bcardiovascular problems/change in beta-blocker prescription (n = 4), inadequate performance (n = 4), thrombocytopenia (n = 1);
cback injury (n = 2);
dincomplete questionnaire (n = 1);
eincomplete questionnaire (n = 2);
fnot performed (n = 6);
gtest not yet included in protocol (n = 3), back injury (n = 2), inadequate performance (n = 1), thrombocytopenia (n = 1), technical problems (n = 1);
hinsufficient wear time (n = 16), technical problems (n = 6), initialization/download failure (n = 4).
iincomplete questionnaire (n = 5).
A higher score for physical activity and functioning scales indicated a higher physical activity level and better HRQoL, respectively. A higher score on fatigue, symptom scales and distress indicated worse HRQoL and higher levels of fatigue and distress, respectively.
Effects of ≥10 physiotherapy sessions on primary and secondary outcome measures in patients treated with auto-SCT.
| Users (n = 72) | Non-users (n = 25) | β (95%CI) | |||
|---|---|---|---|---|---|
| T0 | T1 | T0 | T1 | ||
| VO2peak (mL/kg/min) | 21.0 (4.8) | 25.2 (6.0) | 22.8 (5.8) | 25.0 (7.9) | 1.8 (-0.1;3,8) |
| Wpeak (Watt/kg) | 1.9 (0.5) | 2.4 (0.7) | 2.0 (0.6) | 2.4 (0.8) | 0.1 (-0.04;0.2) |
| Chair stand test (number) | 15.3 (4.5) | 18.2 (5.6) | 14.4 (5.0) | 17.1 (4.2) | 0.3 (-1.0;1.7) |
| Grip strength (kg) | 35.7 (10.4) | 40.7 (11.5) | 37.6 (10.2) | 42.3 (12.9) | 0.5 (-1.5;2.6) |
| Physical fatigue | 13.8 (4.5) | 10.8 (4.8) | 13.8 (4.6) | 9.5 (4.4) | 0.8 (-0.8;2.4) |
| General fatigue | 13.2 (4.0) | 11.1 (4.9) | 12.8 (4.3) | 10.1 (3.9) | 0.5 (-1.1;2.2) |
| Mental fatigue | 10.3 (4.6) | 9.9 (4.5) | 9.9 (4.3) | 9.2 (3.7) | 0.5 (-1.1;2.2) |
| Reduced activity | 12.8 (4.4) | 10.4 (4.4) | 13.3 (4.2) | 9.7 (4.1) | 0.9 (-0.5;2.3) |
| Reduced motivation | 9.1 (3.8) | 8.3 (3.2) | 9.9 (4.0) | 8.0 (3.5) | 0.5 (-0.7;1.8) |
| BMI (kg/m2) | 25.3 (4.6) | 25.9 (4.7) | 25.6 (2.7) | 26.1 (3.1) | 0.1 (-0.5;0.6) |
| Sum skinfolds (mm) | 60.9 (24.7) | 64.3 (26.5) | 61.9 (20.4) | 64.0 (21.1) | 0.9 (-4.2;6.0) |
| Maximal torque m. quadriceps (Nm) | 140.8 (46.6) | 167.2 (51.2) | 156.9 (64.5) | 177.2 (71.3) | 3.9 (-8.5;16.3) |
| Accelerometry (cpm) | 191.8 (81.7) | 238.6 (87.3) | 196.8 (116.6) | 265.8 (169.8) | -23.1 (-67.3;21.1) |
| PASE-score | 89.1 (88.6) | 132.6 (94.1) | 81.1 (62.2) | 94.9 (74.7) | 35.0 (0.9;69.1) |
| Global quality of life | 61.2 (19.1) | 71.9 (20.1) | 65.0 (19.5) | 81.0 (10.6) | -6.5 (-13.5;0.4) |
| Physical functioning | 73.6 (17.1) | 82.2 (18.0) | 77.3 (18.9) | 87.7 (14.6) | -2.6 (-7.4;2.1) |
| Role functioning | 57.2 (31.4) | 75.9 (27.4) | 73.3 (25.0) | 81.3 (30.2) | 2.8 (-8.5;14.1) |
| Emotional functioning | 83.1 (16.8) | 85.3 (16.1) | 80.0 (17.5) | 88.3 (13.4) | -5.3 (-10.8;0.2) |
| Cognitive functioning | 84.3 (19.6) | 81.9 (20.5) | 83.3 (18.0) | 86.0 (14.2) | -4.9 (-11.5;1.7) |
| Social functioning | 70.8 (26.2) | 83.1 (21.9) | 78.7 (25.2) | 90.0 (13.6) | -4.1 (-12.5;4.3) |
| Disease symptoms | 16.9 (12.4) | 18.3 (13.4) | 21.0 (16.8) | 19.8 (18.5) | 0.6 (-5.2;6.5) |
| Side effects | 21.6 (9.7) | 10.7 (7.5) | 21.9 (13.2) | 13.0 (10.5) | -1.8 (-6.3;2.6) |
| Anxiety | 4.3 (3.4) | 4.3 (3.8) | 4.7 (3.5) | 3.2 (1.8) | 1.3 (0.2;2.3) |
| Depression | 3.9 (3.8) | 3.4 (3.5) | 4.2 (3.2) | 2.1 (1.4) | 1.5 (0.5;2.5) |
Data are mean (±SD).
Abbreviation: BMI: Body Mass Index; PASE: Physical Activity Scale for the Elderly
*p<0.05.
±Physical fitness assessments: users (n = 69), non-users (n = 24).
#Adjusted for age, gender, education level and including random intercept.
+Patients assessed at the AMC only.
‡Patients with multiple myeloma only.
Missing data due to
atechnical problems (n = 8), leakage of/took off face mask/inadequate performance (n = 8), cardiovascular problems (n = 4), change in beta-blockers prescription (n = 2), thrombocytopenia (n = 1);
bcardiovascular problems/change in beta-blockers prescription (n = 4), inadequate performance (n = 4), thrombocytopenia (n = 1);
cback injury (n = 2);
dincomplete questionnaire (n = 1);
eincomplete questionnaire (n = 2);
fnot performed (n = 6);
gtest not yet included in protocol (n = 3), back injury (n = 2), inadequate performance (n = 1), thrombocytopenia (n = 1), technical problems (n = 1);
hinsufficient wear time (n = 16), technical problems (n = 6), initialization/download failure (n = 4).
iincomplete questionnaire (n = 5).
A higher score for physical activity and functioning scales indicated a higher physical activity level and better HRQoL, respectively. A higher score on fatigue, symptom scales and distress indicated worse HRQoL and higher levels of fatigue and distress, respectively.